Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

被引：0
|
作者：
Moebius, HJ
Reisberg, B
Schmitt, F
Doody, R
机构：
[1] Merz Pharmaceut GmbH, Res & Dev, Frankfurt, Germany
[2] NYU, Sch Med, New York, NY USA
[3] Univ Kentucky, Lexington, KY USA
[4] Baylor Coll Med, Houston, TX 77030 USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2003年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S388 / S389
页数：2
相关论文
共 50 条
  • [1] Long-term treatment with the NMDA antagonist, memantine:: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease
    Ferris, SH
    Schmitt, FA
    Doody, R
    Möbius, HJ
    Stöffler, A
    Reisberg, B
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 258 - 259
  • [2] Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.
    Ferris, SH
    Schmitt, FA
    Doody, RS
    Moebius, H
    Stoeffler, A
    Reisberg, BJ
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S77 - S78
  • [3] Long-term treatment with the NMDA antagonist memantine:: Results of a 24-week, open-label extension study in moderately severe-to-severe Alzheimer's disease
    Reisberg, B
    Ferris, S
    Möbius, HJ
    Schmitt, F
    Doody, R
    [J]. NEUROBIOLOGY OF AGING, 2002, 23 (01) : S555 - S555
  • [4] A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Reisberg, B
    Doody, R
    Stöffler, A
    Schmitt, F
    Ferris, S
    Möbius, HJ
    [J]. ARCHIVES OF NEUROLOGY, 2006, 63 (01) : 49 - 54
  • [5] Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease
    Bakchine, S.
    Rainer, M.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S529 - S529
  • [6] A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease
    Farlow, Martin R.
    Grossberg, George T.
    Sadowsky, Carl H.
    Meng, Xiangyi
    Velting, Drew M.
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2015, 29 (02): : 110 - 116
  • [7] Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Takase, Takao
    Ohbayashi, Toshio
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (03) : 232 - 239
  • [8] LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
    Ketter, Terence A.
    Sarma, Kaushik
    Silva, Robert
    Kroger, Hans
    Cucchiaro, Josephine
    Loebel, Antony
    [J]. DEPRESSION AND ANXIETY, 2016, 33 (05) : 424 - 434
  • [9] A Long-Term, Open-Label Extension Study Evaluating the Safety of Extended-Release Memantine (28 mg) in Patients with Moderate to Severe Alzheimer's Disease
    Graham, Stephen M.
    Perhach, James
    [J]. ANNALS OF NEUROLOGY, 2011, 70 : S59 - S59
  • [10] Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
    Wallace, D. J.
    Hobbs, K.
    Clowse, M. E. B.
    Petri, M.
    Strand, V.
    Pike, M.
    Merrill, J. T.
    Leszczynski, P.
    Neuwelt, C. M.
    Jeka, S.
    Houssiau, F.
    Keiserman, M.
    Ordi-Ros, J.
    Bongardt, S.
    Kilgallen, B.
    Galateanu, C.
    Kalunian, K.
    Furie, R.
    Gordon, C.
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (04) : 534 - 543
12345